摘要
Abstract
Objective To observe the efficacy of sintilimab combined with platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC)patients and its impact on serum Notch1 and Dickkopf-1 levels.Methods A total of 106 patients with advanced NSCLC admitted from selected and randomly divided into two groups using a random number table.The single group was treated with platinum-based chemotherapy,while the combination group was treated with sintilimab combined with platinum-based chemotherapy.The objective response rate,disease control rate,Notch1 mRNA,Dickkopf-1,T lymphocyte subsets,tumor markers,and adverse reaction rates were compared between the two groups.Results The disease control rate was higher in the combination therapy group than in the single-agent group(P<0.05).There was no significant difference in objective response rates between the two groups(P>0.05).Pre-treatment study-related indicators showed no significant differences between the two groups(P>0.05).After three treatment cycles,both groups showed decreased Notch1 mRNA and Dickkopf-1 levels compared to baseline.The combined therapy group exhibited lower levels than the single-agent group after three cycles(P<0.05).After three treatment cycles,the combined therapy group exhibited higher CD3+,CD4+,and CD4+/CD8+ratios compared to pre-treatment levels and the monotherapy group after three cycles.Conversely,CD8+levels were lower than pre-treatment and monotherapy group levels after three cycles(P<0.05).No significant differences were observed in T lymphocyte subsets between monotherapy groups before and after treatment(P>0.05).After three treatment cycles,both groups showed decreased levels of carbohydrate antigen 125(CA125),squamous cell carcinoma antigen(SCCA),and carcinoembryonic antigen(CEA)compared to baseline.The combined therapy group exhibited lower levels than the single-therapy group after three cycles(P<0.05).The incidence of adverse reactions was comparable between groups(3.77%in the single-agent group vs.7.55%in the combination group;P>0.05).Conclusion Sintilimab combined with platinum-based chemotherapy in the treatment of advanced NSCLC can improve immune function,inhibit the expression of Notch1,Dickkopf-1,and tumor markers,and increase the objective response rate.关键词
信迪利单抗/化疗/非小细胞肺癌/T淋巴细胞亚群/肿瘤标志物Key words
Sintilimab/Chemotherapy/Non-small cell lung cancer/T lymphocyte subsets/Tumor markers分类
医药卫生
